GetTopicDetailResponse(id=877631e09af, topicName=分子靶向治療, introduction=分子靶向治療, content=null, image=null, comments=1, allHits=1850, url=https://h5.medsci.cn/topic?id=31709, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=4307, tagList=[TagDto(tagId=4307, tagName=分子靶向治療)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2161857, encodeId=de06216185e1e, content=高達(dá)50%的<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#膽管癌#</a>可能是<a href='/topic/show?id=877631e09af' target=_blank style='color:#2F92EE;'>#分子靶向治療#</a>的潛在受益者。幾項(xiàng)規(guī)模較小的臨床試驗(yàn)顯示了二線(xiàn)以上靶向治療的潛力。比如<a href='/topic/show?id=5ae0e40125' target=_blank style='color:#2F92EE;'>#FGFR2#</a>、<a href='/topic/show?id=f5d71312e50' target=_blank style='color:#2F92EE;'>#NTRK#</a>、<a href='/topic/show?id=4942941e83' target=_blank style='color:#2F92EE;'>#IDH1#</a>、<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>、<a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a>等<a href='/topic/show?id=e6924180936' target=_blank style='color:#2F92EE;'>#基因突變#</a>。以及<a href='/topic/show?id=85cd50561c3' target=_blank style='color:#2F92EE;'>#微衛(wèi)星不穩(wěn)定性#</a>MSI的情況，這些相關(guān)指標(biāo)的檢測(cè)也將會(huì)為膽管癌患者的精準(zhǔn)治療打下相應(yīng)的治療基礎(chǔ)。
事實(shí)上，其它<a href='/topic/show?id=aa0582e6946' target=_blank style='color:#2F92EE;'>#腫瘤#</a>也是一樣的，各個(gè)不同的腫瘤都應(yīng)該按這個(gè)思路研究一遍，對(duì)于象<a href='/topic/show?id=33771982175' target=_blank style='color:#2F92EE;'>#三陰性乳腺癌#</a>，<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小細(xì)胞肺癌#</a>，<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，同樣如此，梅斯各位會(huì)員們，你們?nèi)绻信d趣，要盡快研究，這是一個(gè)很好的方向，當(dāng)然，也可以申請(qǐng)<a href='/topic/show?id=ca2e4095eaf' target=_blank style='color:#2F92EE;'>#國(guó)家自然科學(xué)基金#</a><a href='/topic/show?id=cebd410388c' target=_blank style='color:#2F92EE;'>#國(guó)自然基金#</a>, objectTitle=真實(shí)數(shù)據(jù)，高達(dá)50%的膽管癌是分子靶向治療的潛在受益者，有機(jī)會(huì)活得更好、更長(zhǎng)！, objectType=article, longId=794442, objectId=b596e944427e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=b596e944427e, replyNumber=0, likeNumber=235, createdTime=2023-10-10, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b596e944427e, moduleTitle=真實(shí)數(shù)據(jù)，高達(dá)50%的膽管癌是分子靶向治療的潛在受益者，有機(jī)會(huì)活得更好、更長(zhǎng)！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b596e944427e)], followStatus=false, userIsMember=false, type=1, lengthMark=1)]
梅斯話(huà)題小助手
2020-05-29
